Harel chief economist: The potential contribution of acquired companies moved overseas is lost to the Israeli economy.
Argus's CEO and CMO talk about their competitive advantage and how they might expand from car cybersecurity.
Ishay Davidi's FIMI Opportunity Funds has signed an MOU to invest NIS 125 million in the Migdal Ha'emek-based electronics company.
Amos Luzon is the latest bidder for the company.
Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.
More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.
Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.